FDA Calls Out Korean Manufacturer Over Contamination Concerns

International Pharmaceutical Regulatory Monitor
A A
An FDA inspection of Korean sterile OTC drug manufacturer Hanlim Pharm in January turned up multiple failures to follow procedures for preventing product contamination.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $157.00